WASHINGTON, May 27 (UPI) --As cancer detection and treatment are now handled in many cases at the genetic level -- such as tests for genetic mutations among potential patients -- a team of researchers has …
United Press International · 1 day ago
These cancer gene panel tests may be doing more harm than good by providing useless results to patients, an international group of scientists warned recently. International researchers are opposing genetic tests that …
National Monitor · 1 day ago
breast cancer
In-depth coverage >
While advances in technology have made multigene testing, or "panel testing," for genetic mutations that increase the risk of breast or other cancers an option, authors of a review published today in the New England …
News-Medical · 15 hours ago
More from Bing News
Eli Lilly and AstraZeneca are combining two cancer drugs in a clinical trial against tumors that are solid in the latest sign such cocktails might be what lies ahead in fighting the deadly disease. The experimental …
Watch List News · 9 hours ago
The team, writing in this week's edition of the New England Journal of Medicine, said the finding "underscores the need to consider fundamental changes in the approach to diagnosing prostate cancer". And false-negative results can give some men a false ... · 1 day ago
Armune Bioscience, the Kalamazoo-based cancer diagnostic startup, has developed what it calls “the world’s only tumor-specific, non-PSA blood test designed to help doctors detect prostate cancer.” Called Apifiny, the test is now available nationally ...
Xconomy · BySarah Schmid · 1 day ago
A new gene test can help oncologists by providing deeper insights into tumors and reduce the use of unnecessary chemotherapy for some breast cancer patients. Launched by genetics and genomics company ILife …
Med India · 1 day ago
Pharmaceutical firms Eli Lilly and AstraZeneca will combine their cancer drugs in a fresh clinical trial against tumours. Anti-PD-L1 immunotherapy drug dubbed MEDI4736 by AstraZeneca will undergo testing together …
DelhiDailyNews · 14 hours ago
SALT LAKE CITY, May 29, 2015 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test
Financial Content · 16 hours ago
Hereditary Cancer
Bristol and other companies are developing diagnostic tests to assess PD-L1 expression ... Other studies released Friday showed Opdivo shrank tumors in patients with liver cancer, and Merck’s anti-PD-1 drug Keytruda shrank head and neck tumors.
Wall Street Journal · 1 hour ago